"I think it's important here that we notice that we the public, we the people, developed this drug. We paid for this drug, we led and developed all the patents to create PrEP [the commonly known name for Truvada] and then that patent has been privatized, despite the fact that the patent is owned by the public, who refused to enforce it," the representative said.
“我認(rèn)為重要的是，我們要注意到，我們公眾，我們?nèi)嗣瘢_發(fā)了這種藥物。我們?yōu)檫@種藥物支付了費(fèi)用，我們領(lǐng)導(dǎo)并開發(fā)了所有的專利，創(chuàng)建了PrEP(特魯瓦達(dá)的俗稱)，然后該專利就被私有化了，盡管該專利屬于拒絕執(zhí)行該專利的公眾。”
"There's no reason this should be $2,000 a month. People are dying because of it," she added.
“沒有理由每月支付2000美元。人們因此而死亡，”她補(bǔ)充道。
As Ocasio-Cortez explained, the research that showed Truvada was effective at preventing HIV in humans, despite a user's potentially risky sexual activity, was almost entirely funded by U.S. taxpayers, according to The Washington Post. The U.S. government patented the treatment back in 2015, but it currently does not receive any profit from the drug. Instead, Gilead, which originally developed the drug for other treatments, has argued that the patent is not valid and continues to rake in billions annually.
據(jù)《華盛頓郵報(bào)》報(bào)道，正如奧卡西奧-科爾特斯所解釋的那樣，這項(xiàng)研究表明特魯瓦達(dá)在預(yù)防人類感染艾滋病毒方面是有效的，盡管使用者有潛在的危險(xiǎn)性行為，而且?guī)缀跬耆怯擅绹?guó)納稅人資助的。美國(guó)政府早在2015年就為這種療法申請(qǐng)了專利，但目前還沒有從這種藥物中獲得任何利潤(rùn)。相反，最初為其他治療方法開發(fā)這種藥物的吉利德辯稱，該專利無效，并繼續(xù)以每年數(shù)十億美元的速度暴利。
In fact, since Truvada was approved as an effective HIV treatment, Gilead has steadily increased its price. A 2018 report by NPR explained that the drug's wholesale price had increased 45 percent over the past six years. Although most health insurance in the U.S. covers Truvada, that does not benefit the millions of Americans who are not insured.
事實(shí)上，自從特魯瓦達(dá)被批準(zhǔn)為一種有效的艾滋病毒治療，吉利德已經(jīng)穩(wěn)步提高了它的價(jià)格。美國(guó)國(guó)家公共電臺(tái)2018年的一份報(bào)告解釋說，這種藥物的批發(fā)價(jià)格在過去六年中上漲了45%。盡管美國(guó)的大多數(shù)醫(yī)療保險(xiǎn)都包括特魯瓦達(dá)醫(yī)保，但這并沒有惠及數(shù)百萬(wàn)沒有醫(yī)保的美國(guó)人。
"With the amount of effort and time and taxpayer money that went into it, for CDC (the Centers for Disease Control and Prevention) and Gilead not to come to an agreement, so the taxpayer could get some of that money, is really unconscionable,'' Thomas Folks, who first researched Truvada's ability to prevent HIV in monkeys, told the Post earlier this year.
“花了這么多精力、時(shí)間和納稅人的錢，美國(guó)疾病控制和預(yù)防中心和吉利德沒有達(dá)成協(xié)議，所以納稅人可以得到一部分錢，這實(shí)在是太不合理了。” 托馬斯·福克斯是第一個(gè)研究特魯瓦達(dá)在猴子身上預(yù)防艾滋病的能力的人，他在今年早些時(shí)候告訴《華盛頓郵報(bào)》。
譯文由可可原創(chuàng)，僅供學(xué)習(xí)交流使用，未經(jīng)許可請(qǐng)勿轉(zhuǎn)載。
評(píng)論
打印
